Thermo Fisher Scientific Inc (TMO) Analyst Ratings & Price Targets

Thermo Fisher Scientific Inc

TMO · NYSE

Analyst Consensus

Buy

21 analysts

$575

Current

—

Low

$630

Average

—

High

Average target implies +9.63% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy across 21 analysts, with a mean price target of $630. The supplied consensus does not report low or high targets, so the target cluster and dispersion cannot be measured. No named analyst is identified as most or least bullish. The evidence also records no analyst rating or target revisions during the past week, leaving the direction of revisions undetermined. The substantive disagreement behind the target range cannot be specified from the available data; the evidence instead points to the central debate over whether stronger demand, acquisitions and margin gains can continue as bioproduction and AI opportunities expand while execution and competition risks increase.

Rating Actions

No individual rating actions have been captured for TMOyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

CITIGROUP

CO FORECST

DEUTSCHE BK SEC

EDWARD JONES

EVERCORE ISI

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

KEYBANC CAP MKT

LEERINK PARTNRS

MORGAN STANLEY

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: TMO
Type: Stock
Sector: Industrials
Industry: Industrial Machinery/Components
Country: North America
Exchange: NYSE

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Key Issues

Bullish view

Thermo Fisher is expanding bioproduction capabilities, and the supplied evidence identifies stronger demand as a driver of its raised 2026 outlook. Continued biopharmaceutical activity could support instruments, consumables and services.

Bearish view

Competition is intensifying, and the evidence specifically flags execution as a key requirement. If customers delay production investment or Thermo Fisher executes poorly, bioproduction growth may not sustain momentum.

Analyst Consensus

See all

Buy